Breast Cancer in Younger Women


The definition of “young” in the context of breast cancer differs considerably according to the analyzed topics, and according to the reporting people. In general, women are considered young if diagnosed with breast cancer before 35 years of age.


Breast Cancer Breast Cancer Patient Breast Cancer Risk Clin Oncol Breast Cancer Survivor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al SEER Cancer Statistics Review, 1975–2005, National Cancer Institute. Bethesda, MD. 2008. http://seercancergov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site 2008Google Scholar
  2. 2.
    Bouchardy C, Fioretta G, Verkooijen HM, Vlastos G, Schaefer P, Delaloye JF, et al Recent increase of breast cancer incidence among women under the age of forty. Br J Cancer. 2007 Jun 4;96(11):1743–6PubMedGoogle Scholar
  3. 3.
    WHO World health organization. Mortality database. <http://www-depdbiarcfr/who>. Accessed 20.11.2007Google Scholar
  4. 4.
    NBCC, National Breast Cancer Coalition. Facts about breast cancer in the United States: Year 2007. <http://wwwstopbreastcancerorg/bin/indexasp? Strid=427&depid=9&nid=2>. Accessed 24.11.2007Google Scholar
  5. 5.
    Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst. 1994;16:35–42Google Scholar
  6. 6.
    Althuis MD, Brogan DD, Coates RJ, Daling JR, Gammon MD, Malone KE, et al Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003 Mar; 14(2):151–60PubMedGoogle Scholar
  7. 7.
    Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996 Jan 1;77(1):97–103PubMedGoogle Scholar
  8. 8.
    Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002 Feb; 13(2):273–9PubMedGoogle Scholar
  9. 9.
    Maggard MA, O’Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse out-comes? J Surg Res. 2003 Jul; 113(1):109–13PubMedGoogle Scholar
  10. 10.
    de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, et al Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993 Apr 24; 341(8852):1039–43PubMedGoogle Scholar
  11. 11.
    Lethaby AE, Mason BH, Holdaway IM, Kay RG. Age and ethnicity as prognostic factors influencing overall survival in breast cancer patients in the Auckland region. Auckland Breast Cancer Study Group. NZ Med J. 1992 Dec 9;105(947):485–8Google Scholar
  12. 12.
    Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, et al Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994 May;12(5):888–94PubMedGoogle Scholar
  13. 13.
    Swanson GM, Lin CS. Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst. 1994:16:69–77Google Scholar
  14. 14.
    Vanlemmens L, Hebbar M, Peyrat JP, Bonneterre J. Age as a prognostic factor in breast cancer. Anticancer Res. 1998 May–June;18(3B):1891–6PubMedGoogle Scholar
  15. 15.
    Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer. 1996 Dec;74(11):1796–800PubMedGoogle Scholar
  16. 16.
    Barchielli A, Balzi D. Age at diagnosis, extent of disease and breast cancer survival: a population-based study in Florence, Italy. Tumori. 2000 Mar–Apr;86(2):119–23PubMedGoogle Scholar
  17. 17.
    Crowe JP, Jr, Gordon NH, Shenk RR, Zollinger RM, Jr., Brumberg DJ, Shuck JM. Age does not predict breast cancer outcome. Arch Surg. 1994 May;129(5):483–7; discussion 7–8PubMedGoogle Scholar
  18. 18.
    Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST. Stage 0 to stage III breast cancer in young women. J Am Coll Surg. 2000 May; 190(5):523–9PubMedGoogle Scholar
  19. 19.
    Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population-based study. BMJ (Clinical Research ed.) 2000 Feb 19;320(7233): 474–8Google Scholar
  20. 20.
    Richards MA, Gregory WM, Smith P, Millis RR, Fentiman IS, Rubens RD. Age as prognostic factor in premenopausal breast cancer. Lancet. 1993 Jun 5;341(8858):1484–5PubMedGoogle Scholar
  21. 21.
    Manuel JC, Burwell SR, Crawford SL, Lawrence RH, Farmer DF, Hege A, et al Younger women’s perceptions of coping with breast cancer. Cancer Nurs. 2007 Mar–Apr; 30(2):85–94PubMedGoogle Scholar
  22. 22.
    Tai P, Cserni G, Van De Steene J, Vlastos G, Voordeckers M, Royce M, et al Modeling the effect of age in T1–2 breast cancer using the SEER database. BMC Cancer. 2005;5:130PubMedGoogle Scholar
  23. 23.
    Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, et al BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast. 2007;16(3):280–92PubMedGoogle Scholar
  24. 24.
    Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999 June 2;91(11):943–9PubMedGoogle Scholar
  25. 25.
    Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, et al BRCA-associated breast cancer in young women. J Clin Oncol. 1998 May 1; 16(5):1642–9PubMedGoogle Scholar
  26. 26.
    Turchetti D, Cortesi L, Federico M, Bertoni C, Mangone L, Ferrari S, et al BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer. Eur J Cancer. 2000;36(16):2083–9PubMedGoogle Scholar
  27. 27.
    Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, et al Distinct molecular pathogeneses of earlyonset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res. 1999 Apr 15; 59(8):2011–7PubMedGoogle Scholar
  28. 28.
    Fackenthal JD, Olopade OI. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev. 2007 Dec; 7(12):937–48Google Scholar
  29. 29.
    Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002 Jan; 7(1):3–15PubMedGoogle Scholar
  30. 30.
    Pike MC, Henderson BE, Krailo MD, Duke A, Roy S. Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet. 1983 Oct 22;2(8356):926–30PubMedGoogle Scholar
  31. 31.
    Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L. Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat. 1998; 50(2):175–84PubMedGoogle Scholar
  32. 32.
    Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996 June 22;347(9017): 1713–27Google Scholar
  33. 33.
    Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, et al A prospective study of oral contraceptive use and risk of breast cancer (Nurses’ Health Study, United States). Cancer Causes Control. 1997 Jan; 8(1): 65–72PubMedGoogle Scholar
  34. 34.
    Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ (Clinical Research ed.) 2007 Sept 29; 335(7621):651Google Scholar
  35. 35.
    Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, et al Oral contraceptives and the risk of breast cancer. N Eng J Med. 2002 Jun 27;346(26): 2025–32Google Scholar
  36. 36.
    Figueiredo JC, Bernstein L, Capanu M, Malone KE, Lynch CF, Anton-Culver H, et al. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group. J Clin Oncol. 2008 Mar 20;26(9):1411–8PubMedGoogle Scholar
  37. 37.
    Bermejo-Pérez M, Márquez-Calderón S, Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer. 2007; 121(2):225–31PubMedGoogle Scholar
  38. 38.
    Colditz GA, Feskanich D, Chen WY, Hunter DJ, Willett WC. Physical activity and risk of breast cancer in premenopausal women. Br J Cancer. 2003 Sep 1;89(5):847–51PubMedGoogle Scholar
  39. 39.
    Key TJ, Pike MC. The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol. 1988 Jan;24(1):29–43PubMedGoogle Scholar
  40. 40.
    van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, et al Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000 Sep 15; 152(6):514–27PubMedGoogle Scholar
  41. 41.
    Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet. 1990 Apr 21; 335(8695):939–40PubMedGoogle Scholar
  42. 42.
    Schernhammer ES. In-utero exposures and breast cancer risk: joint effect of estrogens and insulin-like growth factor? Cancer Causes Control. 2002 Aug;13(6):505–8PubMedGoogle Scholar
  43. 43.
    Michels KB, Trichopoulos D, Robins JM, Rosner BA, Manson JE, Hunter DJ, et al Birthweight as a risk factor for breast cancer. Lancet. 1996 Dec 7;348(9041):1542–6PubMedGoogle Scholar
  44. 44.
    Panagiotopoulou K, Katsouyanni K, Petridou E, Garas Y, Tzonou A, Trichopoulos D. Maternal age, parity, and pregnancy estrogens. Cancer Causes Control. 1990 Sep;1(2): 119–24PubMedGoogle Scholar
  45. 45.
    Carmichael A, Sami AS, Dixon JM. Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionizing radiation. Eur J Surg Oncol. 2003 June; 29(5):475–9PubMedGoogle Scholar
  46. 46.
    Land CE, Tokunaga M, Koyama K, Soda M, Preston DL, Nishimori I, et al Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950–1990. Radiat Res. 2003 Dec;160(6):707–17PubMedGoogle Scholar
  47. 47.
    Pukkala E, Kesminiene A, Poliakov S, Ryzhov A, Drozdovitch V, Kovgan L, et al. Breast cancer in Belarus and Ukraine after the Chernobyl accident. Int J Cancer. 2006 Aug 1;119(3):651–8PubMedGoogle Scholar
  48. 48.
    Guibout C, Adjadj E, Rubino C, Shamsaldin A, Grimaud E, Hawkins M, et al Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol. 2005 Jan 1;23(1):197–204PubMedGoogle Scholar
  49. 49.
    Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, et al Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 2004 Oct 19;141(8):590–7PubMedGoogle Scholar
  50. 50.
    Korenman SG. The endocrinology of breast cancer. Cancer. 1980 Aug 15;46(4 Suppl):874–8PubMedGoogle Scholar
  51. 51.
    Agnese DM, Yusuf F, Wilson JL, Shapiro CL, Lehman A, Burak WE Jr. Trends in breast cancer presentation and care according to age in a single institution. Am J Surg. 2004 Oct;188(4):437–9PubMedGoogle Scholar
  52. 52.
    Foxcroft LM, Evans EB, Porter AJ. The diagnosis of breast cancer in women younger than 40. Breast (Edinburgh, Scotland). 2004 Aug;13(4):297–306Google Scholar
  53. 53.
    Di Nubila B, Cassano E, Urban LABD, Fedele P, Abbate F, Maisonneuve P, et al. Radiological features and pathological-biological correlations in 348 women with breast cancer under 35 years old. Breast. 2006;15(6):744–53PubMedGoogle Scholar
  54. 54.
    Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27, 825 patient evaluations. Radiology. 2002 Oct;225(1):165–75PubMedGoogle Scholar
  55. 55.
    Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA: Cancer J Clin. 2007 Mar–Apr;57(2):75–89Google Scholar
  56. 56.
    Ashley S, Royle GT, Corder A, Herbert A, Guyer PB, Rubin CM, et al Clinical, radiological and cytological diagnosis of breast cancer in young women. Br J Surg. 1989 Aug; 76(8):835–7PubMedGoogle Scholar
  57. 57.
    Ballard-Barbash R, Taplin SH, Yankaskas BC, Ernster VL, Rosenberg RD, Carney PA, et al Breast Cancer Surveillance Consortium: a national mammography screening and out-comes database. Am J Roentgenol. 1997 Oct 1;169(4): 1001–8Google Scholar
  58. 58.
    Buist DSM, Porter PL, Lehman C, Taplin SH, White E. Factors Contributing to Mammography Failure in Women Aged 40–49 Years. J Natl Cancer Inst. 2004 October 6; 96(19):1432–40PubMedCrossRefGoogle Scholar
  59. 59.
    Dubsky PC, Gnant MF, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, et al Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer. Clin Breast Cancer. 2002 Apr;3(1):65–72PubMedGoogle Scholar
  60. 60.
    Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer. 1996 Feb 15;77(4):697–709PubMedGoogle Scholar
  61. 61.
    Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, et al Why are local recurrences after breast-conserving therapy more frequent in younger patients? J Clin Oncol. 1990 Apr;8(4):591–8PubMedGoogle Scholar
  62. 62.
    Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–97PubMedGoogle Scholar
  63. 63.
    Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, Durand JC, et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys. 1989 Oct; 17(4):719–25PubMedGoogle Scholar
  64. 64.
    Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys. 1998;40(4):859–67PubMedGoogle Scholar
  65. 65.
    Jobsen JJ, van der Palen J, Meerwaldt JH. The impact of age on local control in women, with pT1 breast cancer treated with conservative surgery and radiation therapy. Eur J Cancer. 2001 Oct;37(15):1820–7PubMedGoogle Scholar
  66. 66.
    Arriagada R, Le MG, Contesso G, Guinebretiere JM, Rochard F, Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol. 2002 Sep;13(9):1404–13PubMedGoogle Scholar
  67. 67.
    Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, et al Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer. 2004;100(4): 688–93PubMedGoogle Scholar
  68. 68.
    Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Eng J Med. 2002 Aug 22;347(8):567–75Google Scholar
  69. 69.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Eng J Med. 2002;347(16): 1227–32Google Scholar
  70. 70.
    Bartelink H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, et al Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Eng J Med. 2001 Nov 8;345(19): 1378–87Google Scholar
  71. 71.
    Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, et al Can patient-, treatment-and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer. 2003 May;39(7):932–44PubMedGoogle Scholar
  72. 72.
    Bartelink H, Horiot J-C, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007 August 1;25(22):3259–65PubMedGoogle Scholar
  73. 73.
    Radiation dose intensity study in breast cancer in young women. The Netherlands Cancer Institute. Clinical Trials. gov Identifier:NCT00212121Google Scholar
  74. 74.
    Kroman N, Melbye M, Mouridsen HT. Prognostic influence of age at diagnosis in premenopausal breast cancer patients. Scand J Surg. 2002;91(3):305–8PubMedGoogle Scholar
  75. 75.
    Rapiti E, Fioretta G, Verkooijen HM, Vlastos G, Schafer P, Sappino AP, et al. Survival of young and older breast cancer patients in Geneva from 1990 to 2001. Eur J Cancer. 2005 Jul;41(10):1446–52PubMedGoogle Scholar
  76. 76.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005 May 15–20;365(9472):1687–717Google Scholar
  77. 77.
    Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998 Sept 19;352(9132):930–42Google Scholar
  78. 78.
    Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, et al Estrogen receptor status and out-comes of modern chemotherapy for patients with node-positive breast cancer. JAMA. 2006 Apr 12;295(14):1658–67PubMedGoogle Scholar
  79. 79.
    Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, et al Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol. 2000 Feb;18(3):584–90PubMedGoogle Scholar
  80. 80.
    Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007 Mar;8(3): 235–44PubMedGoogle Scholar
  81. 81.
    Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative pheno-type: a population-based study from the California cancer Registry. Cancer. 2007 May 1;109(9):1721–8PubMedGoogle Scholar
  82. 82.
    Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007 Jan 1:109(1):25–32PubMedGoogle Scholar
  83. 83.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365: 1687–717PubMedGoogle Scholar
  84. 84.
    Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, et al Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genom. 2006;7:278Google Scholar
  85. 85.
    Andre F, Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract. 2006 Nov;3(11):621–32Google Scholar
  86. 86.
    Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006 August 10;24(23):3726–34PubMedGoogle Scholar
  87. 87.
    Phase III randomized study of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with various levels of risk for recurrence (TAILORx Trial). PDQ:NCT00310180Google Scholar
  88. 88.
    MINDACT (Microarray In Node-negative Disease may Avoid Chemotherapy): a prospective, randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in node-negative breast cancer. PDQ: NCT00433589Google Scholar
  89. 89.
    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005 Oct;16(10):1569–83PubMedGoogle Scholar
  90. 90.
    Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007 Jul;18(7):1133–44PubMedGoogle Scholar
  91. 91.
    Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, et al Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst. 2001;30:44–51Google Scholar
  92. 92.
    Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, et al Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13–93. J Clin Oncol. 2006 Mar 20;24(9):1332–41PubMedGoogle Scholar
  93. 93.
    Davidson NE, O’Neill AM, Vukov AM, Osborne CK, Martino S, White DR, et al Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 1;23(25): 5973–82PubMedGoogle Scholar
  94. 94.
    Arriagada R, Le MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, et al Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol. 2005 Mar;16(3):389–96PubMedGoogle Scholar
  95. 95.
    Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999 Aug;17(8):2365–70PubMedGoogle Scholar
  96. 96.
    Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006 Mar 1;24(7): 1045–51PubMedGoogle Scholar
  97. 97.
    Castiglione-Gertsch M, O’Neill A, Price KN, Goldhirsch A, Coates AS, Colleoni M, et al Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2003 Dec 17;95(24): 1833–46PubMedGoogle Scholar
  98. 98.
    Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, et al Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol. 2006 Nov 1;24(31):4956–62PubMedGoogle Scholar
  99. 99.
    Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, et al randomized adjuvant trial of Tamoxifen and Goserelin versus Cyclophosphamide, Methotrexate, and Fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer — Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002 December 15;20(24):4621–7PubMedGoogle Scholar
  100. 100.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, et al Goserelin versus Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol. 2002 December 15;20(24):4628–35PubMedGoogle Scholar
  101. 101.
    Roché H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, et al Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomized trial. Ann Oncol. 2006 Aug;17(8):1221–7PubMedGoogle Scholar
  102. 102.
    Roché H, Mihura J, de Lafontan B, Reme-Saumon M, Martel P, Dubois J, et al Castration and tamoxifen vs chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: a randomized trial with a 7 years follow-up. Proc Am Soc Clin Oncol. 1996;15:117Google Scholar
  103. 103.
    Schmid P, Untch M, Kosse V, Bondar G, Vassiljev L, Tarutinov V, et al Leuprorelin acetate every-3-months depot versus Cyclophosphamide, Methotrexate, and Fluorouracil as adjuvant treatment in premenopausal patients with nodepositive breast cancer: The TABLE Study. J Clin Oncol. 2007 June 20;25(18):2509–15PubMedGoogle Scholar
  104. 104.
    Scottish Cancer Trials Breast Group and ICRF Breast Unit. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial. Lancet. 1993;341:1293–8Google Scholar
  105. 105.
    von Minckwitz G, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, et al CMF versus goserelin as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients: a randomized trial (GABG trial IV-A-93). Eur J Cancer. 2006 Aug;42(12): 1780–8Google Scholar
  106. 106.
    Klijn JG, Blamey RW, Boccardo F, Tominaga T, Duchateau L. Sylvester R. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol. 2001;19(2):343–53PubMedGoogle Scholar
  107. 107.
    Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, et al Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006 May;42(7):895–904PubMedGoogle Scholar
  108. 108.
    Robert N, Wang M, Cella D, Martino S, Tripathy D, Ingle J, et al Phase III comparison of tamoxifen versus tamoxifen with ovarian ablation in premenopausal women with axillary node-negative receptor-positive breast cancer ≤3 cm. Proc Am Soc Clin Oncol. 2003;22:5Google Scholar
  109. 109.
    Smith IE, Dowsett M, Yap YS, Walsh G, Lonning PE, Santen RJ, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol. 2006 Jun 1;24(16):2444–7PubMedGoogle Scholar
  110. 110.
    Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347–53PubMedGoogle Scholar
  111. 111.
    Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006 Oct;91(10):3885–90PubMedGoogle Scholar
  112. 112.
    Phase III randomized study of ovarian function suppression in combination with Tamoxifen versus ovarian function suppression in combination with Exemestane versus Tamoxifen alone in premenopausal women with endocrine-responsive breast cancer: SOFT/IBCSG24-02. PDQ: NCT00066690Google Scholar
  113. 113.
    Phase III randomized study of Triptorelin and Exemestane versus Triptorelin and Tamoxifen in premenopausal women with endocrine-responsive breast cancer: TEXT/IBCSG25-02. PDQ:NCT00066703Google Scholar
  114. 114.
    Tamoxifen vs. Anastrozole, alone or in combination with zoledronic acid, in premenopausal, hormone receptor-positive breast cancer patients: ABCSG-12. PDQ:NCT00295646Google Scholar
  115. 115.
    Forward DP, Cheung KL, Jackson L, Robertson JF. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004 Feb 9;90(3):590–4PubMedGoogle Scholar
  116. 116.
    Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, et al Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer. 2007 Sep 17;97(6): 802–8PubMedGoogle Scholar
  117. 117.
    Dana-Farber Cancer Institute. Fulvestrant in premenopausal women with hormone receptor-positive breast cancer, 2005. Clinical Trials. gov Identifier: NCT00146601Google Scholar
  118. 118.
    Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, et al Development of Herceptin resistance in breast cancer cells. Cytometry Part A. 2004;57A(2): 86–93Google Scholar
  119. 119.
    Albanell J, Codony J, Rovira A, Mellado B, Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003;532:253–68PubMedGoogle Scholar
  120. 120.
    Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med. 2001;344(11): 783–92Google Scholar
  121. 121.
    Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, et al Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for breast cancer. N Engl J Med. 2006 February 23;354(8):809–20PubMedGoogle Scholar
  122. 122.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Eng J Med. 2005 Oct 20;353(16):1659–72Google Scholar
  123. 123.
    Robert N, Eiermann W, Pienkowski T, Crown J, Martin M, Pawlicki M, et al BCIRG 006: Docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in nodepositive and high-risk node-negative HER2-positive early breast cancer patients: Quality of life (QOL) at 36 months follow-up. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. 2007;Vol 25(June 20 Suppl):18SGoogle Scholar
  124. 124.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Eng J Med. 2005;353(16):1673–84Google Scholar
  125. 125.
    Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet. 2007;369(9555): 29–36PubMedGoogle Scholar
  126. 126.
    Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E, et al A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat. 2005;94(Suppl 1):3Google Scholar
  127. 127.
    Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792–9PubMedGoogle Scholar
  128. 128.
    Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. The New England journal of medicine. 2007 December 27;357(26): 2666–76PubMedGoogle Scholar
  129. 129.
    Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, et al Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005;23(11):2534–43PubMedGoogle Scholar
  130. 130.
    Cortes J, Baselga J, Kellokumpu-Lehtinen P, et al Openlabel, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. J Clin Oncol. 2005; ASCO Annual Meeting Proceeding (Part II); 23 (1 June Suppl):3068Google Scholar
  131. 131.
    Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, et al Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005;23(11):2502–12PubMedGoogle Scholar
  132. 132.
    Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006 Dec 28;355(26):2733–43PubMedGoogle Scholar
  133. 133.
    Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–7PubMedGoogle Scholar
  134. 134.
    Clayton AJ, Danson S, Jolly S, Ryder WD, Burt PA, Stewart AL, et al Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004 Aug 16;91(4):639–43PubMedGoogle Scholar
  135. 135.
    Lin NU, Winer EP. Brain Metastases: The HER2 Paradigm. Clin Cancer Res. 2007 March 15;13(6):1648–55PubMedGoogle Scholar
  136. 136.
    Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20;26(12):1993–9PubMedGoogle Scholar
  137. 137.
    Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, et al Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005 Aug 10;23(23):5314–22PubMedGoogle Scholar
  138. 138.
    Gligorov J, Azria D, Namer M, Khayat D, Spano JP. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol. 2007;64(2): 115–28PubMedGoogle Scholar
  139. 139.
    Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008 Apr 1:29(2):217–33PubMedGoogle Scholar
  140. 140.
    Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor path-ways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005 January 15;11(2):865s–70PubMedGoogle Scholar
  141. 141.
    Milano A, Dal Lago L, Sotiriou C, Piccart M, Cardoso F. What clinicians need to know about antioestrogen resistance in breast cancer therapy. Eur J Cancer. 2006 Nov; 42(16):2692–705PubMedGoogle Scholar
  142. 142.
    Peoples G, Khoo S, Dehqanzada Z, Mittendorf E, Hueman M, Gurney J, et al Combined clinical trial results of a HER2/neu (E75) vaccine for prevention of recurrence in high-risk breast cancer patients. Breast Cancer Res Treat. 2006;1:S6Google Scholar
  143. 143.
    Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, et al Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol. 2006 May;17(5):750–62PubMedGoogle Scholar
  144. 144.
    Brewer VH, Hahn KA, Rohrbach BW, Bell JL, Baddour LM. Risk factor analysis for breast cellulitis complicating breast-conservation therapy. Clin Infect Dis. 2000 Sep;31(3):654–9PubMedGoogle Scholar
  145. 145.
    Indelicato DJ, Grobmyer SR, Newlin H, Morris CG, Haigh LS, Copeland EM 3rd, et al Delayed breast cellulitis: an evolving complication of breast conservation. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1339–46PubMedGoogle Scholar
  146. 146.
    Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med. 1992 Nov;93(5):543–8PubMedGoogle Scholar
  147. 147.
    Petrek JA, Peters MM, Nori S, Knauer C, Kinne DW, Rogatko A. Axillary lymphadenectomy. A prospective, randomized trial of 13 factors influencing drainage, including early or delayed arm mobilization. Arch Surg. 1990 Mar; 125(3):378–82PubMedGoogle Scholar
  148. 148.
    Budd DC, Cochran RC, Sturtz DL, Fouty WJ Jr. Surgical morbidity after mastectomy operations. Am J Surg. 1978 Feb;135(2):218–20PubMedGoogle Scholar
  149. 149.
    Jamison K, Wellisch DK, Katz RL, Pasnau RO. Phantom breast syndrome. Arch Surg. 1979 Jan;114(1):93–5PubMedGoogle Scholar
  150. 150.
    Ganz PA, Kwan L, Stanton AL, Krupnick JL, Rowland JH, Meyerowitz BE, et al Quality of life at the end of primary treatment of breast cancer: first results from the moving beyond cancer randomized trial. J Natl Cancer Inst. 2004 March 3;96(5):376–87PubMedCrossRefGoogle Scholar
  151. 151.
    Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist. 2006 Feb;11(2):96–110PubMedGoogle Scholar
  152. 152.
    Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol. 2008 February 10;26(5):753–8PubMedGoogle Scholar
  153. 153.
    Nystedt M, Berglund G, Bolund C, Fornander T, Rutqvist LE. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study. J Clin Oncol. 2003 May 1;21(9):1836–44PubMedGoogle Scholar
  154. 154.
    Sverrisdottir A, Fornander T, Jacobsson H, von Schoultz E, Rutqvist LE. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol. 2004 September 15;22(18):3694–9PubMedGoogle Scholar
  155. 155.
    Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007 September 11;69(11):1074–83PubMedGoogle Scholar
  156. 156.
    Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology. 2008 January 15;70(3):200–9PubMedGoogle Scholar
  157. 157.
    Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Eng J Med. 2001 Jun 28;344(26): 1997–2008Google Scholar
  158. 158.
    Demark-Wahnefried W, Hars V, Conaway MR, Havlin K, Rimer BK, McElveen G, et al Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am J Clin Nutr. 1997 May;65(5):1495–501PubMedGoogle Scholar
  159. 159.
    Demark-Wahnefried W, Winer EP, Rimer BK. Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1993 Jul;11(7):1418–29PubMedGoogle Scholar
  160. 160.
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996 May;14(5):1718–29PubMedGoogle Scholar
  161. 161.
    Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications. Breast Cancer Res Treat. 1997 Apr;43(2):183–90PubMedGoogle Scholar
  162. 162.
    Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;(1):105–9PubMedGoogle Scholar
  163. 163.
    Sainsbury JRC, Anderson TJ, Morgan DAL. ABC of breast diseases: breast cancer. BMJ (Clinical Research ed.) 2000 September 23;321(7263):745–50Google Scholar
  164. 164.
    Bentzen S, Overgaard J. Patient-to-patient variability in the expression of radiation-induced normal tissue injury. Semin Radiat Oncol. 1994 Apr;4(2):68–80PubMedGoogle Scholar
  165. 165.
    Lilla C, Ambrosone C, Kropp S, Helmbold I, Schmezer P, von Fournier D, et al Predictive factors for late normal tissue complications following radiotherapy for breast cancer. Breast Cancer Res Treat. 2007;106(1):143–50PubMedGoogle Scholar
  166. 166.
    Bird BRJH, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008 January 1;14(1):14–24PubMedGoogle Scholar
  167. 167.
    Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007 October 9;50(15):1435–41PubMedGoogle Scholar
  168. 168.
    Perez EA, Suman VJ, Davidson NE, Kaufman PA, Martino S, Dakhil SR, et al Effect of Doxorubicin plus Cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol. 2004 Sept 15;22(18):3700–4PubMedGoogle Scholar
  169. 169.
    Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai W-Y, McBride R, et al Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007 February 7;99(3):196–205PubMedGoogle Scholar
  170. 170.
    Le Deley M-C, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, et al Anthracyclines, Mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol. 2007 January 20;25(3): 292–300PubMedGoogle Scholar
  171. 171.
    Smith RE, Bryant J, DeCillis A, Anderson S. acute myeloid leukemia and myelodysplastic syndrome after Doxorubicin-Cyclophosphamide adjuvant therapy for operable breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol. 2003 Apr 1;21(7): 1195–204PubMedGoogle Scholar
  172. 172.
    Monroe AT, Feigenberg SJ, Price Mendenhall N. Angiosarcoma after breast-conserving therapy. Cancer. 2003;97(8):1832–40PubMedGoogle Scholar
  173. 173.
    Osteen RT, Cady B, Friedman M, Kraybill W, Doggett S, Hussey D, et al Patterns of care for younger women with breast cancer. J Natl Cancer Inst. 1994;16:43–6Google Scholar
  174. 174.
    Gomide LB, Matheus JPC, Candido dos Reis FJ. Morbidity after breast cancer treatment and physiotherapeutic performance. Int J Clin Pract. 2007;61(6):972–82PubMedGoogle Scholar
  175. 175.
    Purushotham AD, Bennett Britton TM, Klevesath MB, Chou P, Agbaje OF, Duffy SW. Lymph node status and breast cancer-related lymphedema. Ann Surg. 2007 Jul; 246(1):42–5PubMedGoogle Scholar
  176. 176.
    van der Veen P, De Voogdt N, Lievens P, Duquet W, Lamote J, Sacre R. Lymphedema development following breast cancer surgery with full axillary resection. Lymphology. 2004 Dec;37(4):206–8PubMedGoogle Scholar
  177. 177.
    Pain SJ, Purushotham AD. Lymphoedema following surgery for breast cancer. Br J Surg. 2000 Sep;87(9): 1128–41PubMedGoogle Scholar
  178. 178.
    Perbeck L, Celebioglu F, Svensson L, Danielsson R. Lymph circulation in the breast after radiotherapy and breast conservation. Lymphology. 2006 Mar;39(1):33–40PubMedGoogle Scholar
  179. 179.
    Senkus-Konefka E, Jassem J. Complications of breast-cancer radiotherapy. Clin Oncol (Royal College of Radiologists (Great Britain)). 2006 Apr;18(3):229–35Google Scholar
  180. 180.
    Khatcheressian JL, Wolff AC, Smith TJ, Grunfeld E, Muss HB, Vogel VG, et al American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006 Nov 1;24(31):5091–7PubMedGoogle Scholar
  181. 181.
    National Comprehensive Cancer Network. Clinical practice guidelines in oncology, 2007. http://www.nccn.orgGoogle Scholar
  182. 182.
    US Preventive Services Task Force. Genetic risk assessment and brca/BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med. 2005 Sept 6;143(5):355–61Google Scholar
  183. 183.
    Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998 Apr 16;338(16):1089–96PubMedGoogle Scholar
  184. 184.
    Roche N. Follow-up after treatment for breast cancer in young women Breast (Edinburgh, Scotland). 2006 Dec; 15(Suppl 2):S71–5Google Scholar
  185. 185.
    Krychman ML, Stelling CJ, Carter J, Hudis CA. A case series of androgen use in breast cancer survivors with sexual dysfunctions. J Sexual Med. 2007;4(6):1769–74Google Scholar
  186. 186.
    Hayes DF. Follow-up of patients with early breast cancer. N Engl J Med. 2007; June 14;356(24):2505–13PubMedGoogle Scholar
  187. 187.
    Schover LR. Psychosocial aspects of infertility and decisions about reproduction in young cancer survivors: a review. Med Pediatr Oncol. 1999 Jul;33(1):53–9PubMedGoogle Scholar
  188. 188.
    Wenzel L, Dogan-Ates A, Habbal R, Berkowitz R. Goldstein DP, Bernstein M, et al Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst. 2005;34:94–8Google Scholar
  189. 189.
    Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol. 2004 Oct 15;22(20):4174–83PubMedGoogle Scholar
  190. 190.
    Ganz PA, Greendale GA, Petersen L, Kahn B, Bower JE, Breast cancer in younger women: reproductive and late health effects of treatment. J Clin Oncol. 2003 Nov 15; 21(22):4184–93PubMedGoogle Scholar
  191. 191.
    Thewes B, Meiser B, Taylor A, Phillips KA, Pendlebury S, Capp A, et al Fertility-and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol. 2005 Aug 1;23(22):5155–65PubMedGoogle Scholar
  192. 192.
    Braun M, Hasson-Ohayon I, Perry S, Kaufman B, Uziely B. Motivation for giving birth after breast cancer. Psycho-Oncol. 2005;14(4):282–96Google Scholar
  193. 193.
    Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al American Society of Clinical Oncology Recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006 June 20;24(18):2917–31PubMedGoogle Scholar
  194. 194.
    Coulam C. Neuroendocrinology and ovarian function. In: Scott JR, DiSaia PJ, Hammond CB, et al, editors. Danforth’s obstetrics and gynecology. 6th ed. Philadelphia, PA: Lippincott, 1990, p.57–73Google Scholar
  195. 195.
    Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol. 2006 Dec 20;24(36):5769–79PubMedGoogle Scholar
  196. 196.
    Parulekar WR, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V, et al Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study — NCIC CTG MA.5. J Clin Oncol. 2005 Sept 1;23(25):6002–8PubMedGoogle Scholar
  197. 197.
    Stearns V, Schneider B, Henry NL, Hayes DF, Flockhart DA. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev. 2006 Nov;6(11):886–93Google Scholar
  198. 198.
    Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer. 1990 Feb 15;65(4):847–50PubMedGoogle Scholar
  199. 199.
    Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod (Oxford, England). 1996 Aug;11(8):1620–6Google Scholar
  200. 200.
    Waxman J. Preserving fertility in Hodgkin’s disease. Baillieres Clin Haematol. 1987 Mar;1(1):185–90PubMedGoogle Scholar
  201. 201.
    Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, et al Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005 Oct 20; 23(30):7555–64PubMedGoogle Scholar
  202. 202.
    Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin’s disease. Blood. 1981 Oct;58(4):849–51PubMedGoogle Scholar
  203. 203.
    Oktay K. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation. J Clin Oncol. 2005 Jun 1;23(16):3858–9PubMedGoogle Scholar
  204. 204.
    Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril. 2006 Jul;86(1):70–80PubMedGoogle Scholar
  205. 205.
    Borini A, Bianchi V, Bonu MA, Sciajno R, Sereni E, Cattoli M, et al Evidence-based clinical outcome of oocyte slow cooling. Reprod Biomed Online. 2007 Aug;15(2):175–81PubMedCrossRefGoogle Scholar
  206. 206.
    Kuwayama M. Highly efficient vitrification for cryopreservation of human oocytes and embryos: Cryotop method. Theriogenology. 2007 Jan 1;67(1):73–80PubMedGoogle Scholar
  207. 207.
    Meirow D, Baum M, Yaron R, Levron J, Hardan I, Schiff E, et al Ovarian tissue cryopreservation in hematologic malignancy: ten years’ experience. Leukemia Lymphoma. 2007 Aug;48(8):1569–76PubMedGoogle Scholar
  208. 208.
    Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugieres L, Jouannet P. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod (Oxford, England). 2002 June;17(6):1447–52Google Scholar
  209. 209.
    Newton H. The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Human reproduction update. 1998 May–June;4(3):237–47Google Scholar
  210. 210.
    Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Eng J Med. 2000 Jun 22;342(25):1919Google Scholar
  211. 211.
    Oktay K, Buyuk E, Rosenwaks Z, Rucinski J. A technique for transplantation of ovarian cortical strips to the forearm. Fertil Steril. 2003 Jul;80(1):193–8PubMedGoogle Scholar
  212. 212.
    Oktay K, Buyuk E, Veeck L, Zaninovic N, Xu K, Takeuchi T, et al Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004 Mar 13;363(9412):837–40PubMedGoogle Scholar
  213. 213.
    Radford JA, Lieberman BA, Brison DR, Smith AR, Critchlow JD, Russell SA, et al Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin’s lymphoma. Lancet. 2001 Apr 14;357(9263):1172–5PubMedGoogle Scholar
  214. 214.
    Tryde Schmidt KL, Yding Andersen C, Starup J, Loft A, Byskov AG, Nyboe Andersen A. Orthotopic autotransplantation of cryopreserved ovarian tissue to a woman cured of cancer — follicular growth, steroid production and oocyte retrieval. Reprod Biomed Online. 2004 Apr;8(4):448–53PubMedCrossRefGoogle Scholar
  215. 215.
    Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004 364(9443): 1405–10PubMedGoogle Scholar
  216. 216.
    Meirow D, Levron J, Eldar-Geva T, Hardan I, Fridman E, Zalel Y, et al Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005 Jul 21;353(3):318–21PubMedGoogle Scholar
  217. 217.
    Kim SS, Radford J, Harris M, Varley J, Rutherford AJ, Lieberman B, et al Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation. Hum Reprod (Oxford, England). 2001 Oct;16(10):2056–60Google Scholar
  218. 218.
    Sonmezer M, Shamonki MI, Oktay K. Ovarian tissue cryopreservation: benefits and risks. Cell Tissue Res. 2005 Oct;322(1):125–32PubMedGoogle Scholar
  219. 219.
    Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, et al Effect of pregnancy on overall survival after the diagnosis of early stage breast cancer. J Clin Oncol. 2001 Mar 15;19(6):1671–5PubMedGoogle Scholar
  220. 220.
    Loibl S, Kohl J, Kaufmann M. Reproduction after breast cancer: what advice do we have for our patients? Zentralbl Gynakol. 2005 Jun;127(3):120–4PubMedGoogle Scholar
  221. 221.
    Antonelli NM, Dotters DJ, Katz VL, Kuller JA. Cancer in pregnancy: a review of the literature. Part II. Obstet Gynecol Surv. 1996 Feb;51(2):135–42PubMedGoogle Scholar
  222. 222.
    Antonelli NM, Dotters DJ, Katz VL, Kuller JA. Cancer in pregnancy: a review of the literature. Part I. Obstet Gynecol Surv. 1996 Feb;51(2):125–34PubMedGoogle Scholar
  223. 223.
    Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, et al Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol. 1999 Mar;17(3):855–61PubMedGoogle Scholar
  224. 224.
    Wallack MK, Wolf JA Jr, Bedwinek J, Denes AE, Glasgow G, Kumar B, et al Gestational carcinoma of the female breast. Curr Probl Cancer. 1983 Mar;7(9):1–58PubMedGoogle Scholar
  225. 225.
    Anderson BO, Petrek JA, Byrd DR, Senie RT, Borgen PI. Pregnancy influences breast cancer stage at diagnosis in women 30 years of age and younger. Ann Surg Oncol. 1996 Mar;3(2):204–11PubMedGoogle Scholar
  226. 226.
    Albrektsen G, Heuch I, Kvale G. The short-term and longterm effect of a pregnancy on breast cancer risk: a prospective study of 802, 457 parous Norwegian women. Br J Cancer. 1995 Aug;72(2):480–4PubMedGoogle Scholar
  227. 227.
    Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Eng J Med. 1994 Jul 7;331(1):5–9Google Scholar
  228. 228.
    Wohlfahrt J, Andersen PK, Mouridsen HT, Melbye M. Risk of late-stage breast cancer after a childbirth. Am J Epidemiol. 2001 Jun 1;153(11):1079–84PubMedGoogle Scholar
  229. 229.
    Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, et al Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005 Dec 20;117(6):988–91PubMedGoogle Scholar
  230. 230.
    Ishida T, Yokoe T, Kasumi F, Sakamoto G, Makita M, Tominaga T, et al Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res. 1992 Nov;83(11):1143–9PubMedGoogle Scholar
  231. 231.
    Shen T, Vortmeyer AO, Zhuang Z, Tavassoli FA. High frequency of allelic loss of BRCA2 gene in pregnancy-associated breast carcinoma. J Natl Cancer Inst. 1999 October 6;91(19):1686–7PubMedGoogle Scholar
  232. 232.
    Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet. 1998 Oct 24;352(9137):1359–60PubMedGoogle Scholar
  233. 233.
    Saber A, Dardik H, Ibrahim IM, Wolodiger F. The milk rejection sign: a natural tumor marker. Am Surg. 1996 Dec;62(12):998–9PubMedGoogle Scholar
  234. 234.
    Liberman L, Giess CS, Dershaw DD, Deutch BM, Petrek JA. Imaging of pregnancy-associated breast cancer. Radiology. 1994 Apr 1;191(1):245–8PubMedGoogle Scholar
  235. 235.
    Ahn BY, Kim HH, Moon WK, Pisano ED, Kim HS, Cha ES, et al Pregnancy-and lactation-associated breast cancer: mammographic and sonographic findings. J Ultrasound Med. 2003 May;22(5):491–7; quiz 8–9PubMedGoogle Scholar
  236. 236.
    Yang WT, Dryden MJ, Gwyn K, Whitman GJ, Theriault R. Imaging of breast cancer diagnosed and treated with chemotherapy during pregnancy. Radiology. 2006 Apr 1;239(1):52–60PubMedGoogle Scholar
  237. 237.
    Barthelmes L, Davidson LA, Gaffney C, Gateley CA. Pregnancy and breast cancer. BMJ (Clinical Research ed.) 2005 June 11;330(7504):1375–8Google Scholar
  238. 238.
    Collins JC, Liao S, Wile AG. Surgical management of breast masses in pregnant women. J Reprod Med. 1995 Nov;40(11):785–8PubMedGoogle Scholar
  239. 239.
    Nicklas AH, Baker ME. Imaging strategies in the pregnant cancer patient. Semin Oncol. 2000 Dec;27(6):623–32PubMedGoogle Scholar
  240. 240.
    Max MH, Klamer TW. Pregnancy and breast cancer. South Med J. 1983 Sep;76(9):1088–90PubMedGoogle Scholar
  241. 241.
    Samuels TH, Liu FF, Yaffe M, Haider M. Gestational breast cancer. Canadian Association of Radiologists journal= Journal l’Association canadienne des radiologistes. 1998 June;49(3):172–80PubMedGoogle Scholar
  242. 242.
    Frank G, Shellock EK. Safety of magnetic resonance imaging contrast agents. J Mag Reson Imaging. 1999;10(3):477–84Google Scholar
  243. 243.
    Shao-Pow Lin JJB. MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging. 2007;25(5):884–99PubMedGoogle Scholar
  244. 244.
    Shellock FG, Crues JV. MR procedures: biologic effects, safety, and patient care. Radiology. 2004 Sep;232(3):635–52PubMedGoogle Scholar
  245. 245.
    Benveniste H, Fowler JS, Rooney WD, Moller DH, Backus WW, Warner DA, et al Maternal-fetal in vivo imaging: a combined PET and MRI Study. J Nucl Med. 2003 Sept 1;44(9):1522–30PubMedGoogle Scholar
  246. 246.
    ten Hove CH, Zijlstra-Baalbergen JM, Comans EI, van Elburg RM. An unusual hotspot in a young woman with Hodgkin’s lymphoma. Haematologica. 2008 Jan 1;93(1):e14–5PubMedGoogle Scholar
  247. 247.
    Barker P. Milk fistula: an unusual complication of breast biopsy. J R Coll Surg Edinb. 1988 Apr;33(2):106PubMedGoogle Scholar
  248. 248.
    Schackmuth EM, Harlow CL, Norton LW. Milk fistula: a complication after core breast biopsy. AJR. 1993 Nov; 161(5):961–2PubMedGoogle Scholar
  249. 249.
    Bottles K, Taylor RN. Diagnosis of breast masses in pregnant and lactating women by aspiration cytology. Obstet Gynecol. 1985 Sep;66(3 Suppl):76S–8SPubMedGoogle Scholar
  250. 250.
    Mitre BK, Kanbour AI, Mauser N. Fine needle aspiration biopsy of breast carcinoma in pregnancy and lactation. Acta Cytologica. 1997 July–Aug;41(4):1121–30PubMedGoogle Scholar
  251. 251.
    Novotny DB, Maygarden SJ, Shermer RW, Frable WJ. Fine needle aspiration of benign and malignant breast masses associated with pregnancy. Acta Cytologica. 1991 Nov–Dec; 35(6):676–86PubMedGoogle Scholar
  252. 252.
    Shannon J, Douglas-Jones AG, Dallimore NS. Conversion to core biopsy in preoperative diagnosis of breast lesions: is it justified by results? J Clin Pathol. 2001 Oct;54(10):762–5PubMedGoogle Scholar
  253. 253.
    Loibl S, von Minckwitz G, Gwyn K, Ellis P, Blohmer JU, Schlegelberger B, et al Breast carcinoma during pregnancy. Cancer. 2006;106(2):237–46PubMedGoogle Scholar
  254. 254.
    Stewart A, Webb K, Giles D. Malignant disease in childhood and diagnostic irradiation in utero. Lancet. 1956;2:447Google Scholar
  255. 255.
    Court Brown WM, Doll R, Hill RB. Incidence of leukaemia after exposure to diagnostic radiation in utero. Br Med J. 1960;2(5212):1539–45PubMedGoogle Scholar
  256. 256.
    Diamond EL, Schmerler H, Lilienfeld AM. The relation-ship of intra-uterine radiation to subsequent mortality and development of leukemia in children. A prospective study. Am J Epidemiol. 1973 May;97(5):283–313PubMedGoogle Scholar
  257. 257.
    Delongchamp RR, Mabuchi K, Yoshimoto Y, Preston DL. Cancer mortality among atomic bomb survivors exposed in utero or as young children, October 1950–May 1992. Radiat Res. 1997 Mar;147(3):385–95PubMedGoogle Scholar
  258. 258.
    Puglisi F, Follador A, Minisini AM, Cardellino GG, Russo S, Andreetta C, et al Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005 Feb 1;16(2):263–6PubMedGoogle Scholar
  259. 259.
    Mazze RI, Kallen B. Reproductive outcome after anesthesia and operation during pregnancy: a registry study of 5405 cases. Am J Obstet Gynecol. 1989 Nov;161(5):1178–85PubMedGoogle Scholar
  260. 260.
    Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg. 2003 Jan;138(1):91–8; discussion 9PubMedCrossRefGoogle Scholar
  261. 261.
    Kuerer HM, Gwyn K, Ames FC, Theriault RL. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery. 2002 Jan;131(1):108–10PubMedGoogle Scholar
  262. 262.
    Ruo Redda MG, Verna R, Guarneri A, Sannazzari GL. Timing of radiotherapy in breast cancer conserving treatment. Cancer Treat Rev. 2002 Feb;28(1):5–10PubMedGoogle Scholar
  263. 263.
    Sprung J, Tully MJ, Ziser A. Anaphylactic reactions to Isosulfan blue dye during sentinel node lymphadenectomy for breast cancer. Anesth Analg. 2003 Apr 1;96(4):1051–3PubMedGoogle Scholar
  264. 264.
    Gentilini O, Cremonesi M, Trifiro G, Ferrari M, Baio SM, Caracciolo M, et al Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol. 2004 Sept 1;15(9):1348–51PubMedGoogle Scholar
  265. 265.
    Keleher A, Wendt R, 3rd, Delpassand E, Stachowiak AM, Kuerer HM. The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid. Breast J. 2004 Nov–Dec;10(6):492–5PubMedGoogle Scholar
  266. 266.
    Pandit-Taskar N, Dauer LT, Montgomery L, St. Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med. 2006 July 1;47(7):1202–8PubMedGoogle Scholar
  267. 267.
    Mondi MM, Cuenca RE, Ollila DW, Stewart JHIV, Levine EA. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surgl Oncol. 2007 Jan 1;14(1):218–21Google Scholar
  268. 268.
    Lyman GH, Giuliano AE, Somerfield MR, Benson AB, III, Bodurka DC, Burstein HJ, et al American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early stage breast cancer. J Clin Oncol. 2005 Oct 20;23(30):7703–20PubMedGoogle Scholar
  269. 269.
    Greskovich JF Jr, Macklis RM. Radiation therapy in pregnancy: risk calculation and risk minimization. Semin Oncol. 2000 Dec;27(6):633–45PubMedGoogle Scholar
  270. 270.
    Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005 May;6(5):328–33PubMedGoogle Scholar
  271. 271.
    Antypas C, Sandilos P, Kouvaris J, Balafouta E, Karinou E, Kollaros N, et al Fetal dose evaluation during breast cancer radiotherapy. Int J Radiat Oncol Biol Phys. 1998 Mar 1; 40(4):995–9PubMedGoogle Scholar
  272. 272.
    Petrek JA. Breast cancer during pregnancy. Cancer. 1994 Jul 1;74(1 Suppl):518–27PubMedGoogle Scholar
  273. 273.
    Doll DC, Ringenberg QS Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol. 1989 Oct;16(5):337–46PubMedGoogle Scholar
  274. 274.
    Germann N, Goffinet F, Goldwasser F. Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol. 2004 Jan;15(1):146–50PubMedGoogle Scholar
  275. 275.
    Byrd BF Jr, Bayer DS, Robertson JC, Stephenson SE Jr. Treatment of breast tumors associated with pregnancy and lactation. Ann Surg. 1962 Jun;155:940–7PubMedGoogle Scholar
  276. 276.
    Murray CL, Reichert JA, Anderson J, Twiggs LB. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA. 1984 Nov 9;252(18):2607–8Google Scholar
  277. 277.
    Turchi JJ, Villasis C. Anthracyclines in the treatment of malignancy in pregnancy. Cancer. 1988 Feb 1;61(3):435–40PubMedGoogle Scholar
  278. 278.
    Wiebe VJ, Sipila PE. Pharmacology of antineoplastic agents in pregnancy. Crit Rev Oncol Hematol. 1994 Apr; 16(2):75–112PubMedGoogle Scholar
  279. 279.
    Williams SF, Schilsky RL. Antineoplastic drugs administered during pregnancy. Semin Oncol. 2000 Dec; 27(6):618–22PubMedGoogle Scholar
  280. 280.
    Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74(2):207–20PubMedGoogle Scholar
  281. 281.
    Zemlickis D, Lishner M, Degendorfer P, Panzarella T, Burke B, Sutcliffe SB, et al Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol. 1992 Mar;166(3):781–7PubMedGoogle Scholar
  282. 282.
    Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy: A French national survey. Cancer. 1999;86(11):2266–72PubMedGoogle Scholar
  283. 283.
    Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004 May;5(5):283–91PubMedGoogle Scholar
  284. 284.
    Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol. 2005 Jun 20;23(18):4192–7PubMedGoogle Scholar
  285. 285.
    Hahn KM, Johnson PH, Gordon N, Kuerer H, Middleton L, Ramirez M, et al Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006 Sep 15;107(6):1219–26PubMedGoogle Scholar
  286. 286.
    Gentilini O, Masullo M, Rotmensz N, Peccatori F, Mazzarol G, Smeets A, et al Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options. Eur J Surg Oncol. 2005;31(3):232–6PubMedGoogle Scholar
  287. 287.
    Peccatori F, Martinelli G, Gentilini O, Goldhirsch A. Chemotherapy during pregnancy: what is really safe? Lancet Oncol. 2004;5(7):398PubMedGoogle Scholar
  288. 288.
    Meyer-Wittkopf M, Barth H, Emons G, Schmidt S. Fetal cardiac effects of doxorubicin therapy for carcinoma of the breast during pregnancy: case report and review of the literature. Ultrasound Obstet Gynecol. 2001 Jul;18(1):62–6PubMedGoogle Scholar
  289. 289.
    Achtari C, Hohlfeld P. Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy. Am J Obst Gynecol. 2000 Aug;183(2):511–2Google Scholar
  290. 290.
    Peres RM, Sanseverino MT, Guimaraes JL, Coser V, Giuliani L, Moreira RK, et al Assessment of fetal risk associated with exposure to cancer chemotherapy during pregnancy: a multicenter study. Braz J Med Biol Res. 2001 Dec;34(12):1551–9PubMedGoogle Scholar
  291. 291.
    Reynoso EE, Huerta F. Acute leukemia and pregnancy-fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol. 1994;33(6):709–10PubMedGoogle Scholar
  292. 292.
    Siu BL, Alonzo MR, Vargo TA, Fenrich AL. Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second tri mester of pregnancy. Int J Gynecol Cancer. 2002 July–Aug; 12(4):399–402PubMedGoogle Scholar
  293. 293.
    Eedarapalli P, Biswas N, Coleman M. Epirubicin for breast cancer during pregnancy: a case report. J Reprod Med. 2007 Aug; 52(8):730–2PubMedGoogle Scholar
  294. 294.
    Karp GI, von Oeyen P, Valone F, Khetarpal VK, Israel M, Mayer RJ, et al Doxorubicin in pregnancy: possible transplacental passage. Cancer Treat Rep. 1993 Sep;67(9):773–7Google Scholar
  295. 295.
    De Santis M, Lucchese A, De Carolis S, Ferrazani S, Caruso A. Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl). 2000 Dec;9(4):235–7Google Scholar
  296. 296.
    Gainford MC, Clemons M. Breast cancer in pregnancy: are taxanes safe? Clinical Oncol (Royal College of Radiologists (Great Britain). 2006 Mar;18(2):159Google Scholar
  297. 297.
    Gonzalez-Angulo AM, Walters RS, Carpenter RJ Jr, Ross MI, Perkins GH, Gwyn K, et al Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer. 2004 Oct:5(4):317–9PubMedGoogle Scholar
  298. 298.
    Mendez LE, Mueller A, Salom E, Gonzalez-Quintero VH. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol. 2003 Nov;102(5 Pt 2):1200–2PubMedGoogle Scholar
  299. 299.
    Nieto Y, Santisteban M, Aramendia JM, Fernandez-Hidalgo O, Garcia-Manero M, Lopez G. Docetaxel administered during pregnancy for inflammatory breast carcinoma. Clin Breast Cancer. 2006 Feb;6(6):533–4PubMedGoogle Scholar
  300. 300.
    Potluri V, Lewis D, Burton GV. Chemotherapy with taxanes in breast cancer during pregnancy: case report and review of the literature. Clin Breast Cancer. 2006 Jun;7(2):167–70PubMedGoogle Scholar
  301. 301.
    Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol. 2001 Dec;83(3):599–600PubMedGoogle Scholar
  302. 302.
    Pant S, Landon MB, Blumenfeld M, Farrar W, Shapiro CL. Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol. 2008 March 20;26(9):1567–9PubMedGoogle Scholar
  303. 303.
    Bader AA, Schlembach D, Tamussino KF, Pristauz G, Petru E. Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol. 2007 Jan;8(1):79–81PubMedGoogle Scholar
  304. 304.
    Fanale MA, Uyei AR, Theriault RL, Adam K, Thompson RA. Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clinical Breast Cancer. 2005 Oct;6(4):354–6PubMedGoogle Scholar
  305. 305.
    Sekar R, Stone PR. Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol. 2007 Aug; 110(2 Pt 2): 507–10PubMedGoogle Scholar
  306. 306.
    Watson WJ. Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol. 2005 Mar;105(3):642–3PubMedGoogle Scholar
  307. 307.
    Shrim A, Garcia-Bournissen F, Maxwell C, Farine D, Koren G. Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy — case report and updated literature review. Reprod Toxicol (Elmsford, NY). 2007 June;23(4):611–3Google Scholar
  308. 308.
    Waterston AM, Graham J. Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol. 2006 Jan 10;24(2):321–2PubMedGoogle Scholar
  309. 309.
    Kelly H, Graham M, Humes E, Dorflinger LJ, Boggess KA. O’Neil BH. et al Delivery of a healthy baby after first-trimester maternal exposure to lapatinib. Clin Breast Cancer. 2006 Oct;7(4):339–41PubMedGoogle Scholar
  310. 310.
    Chamness GC, Bannayan GA, Landry LAJ, Sheridan PJ, McGuire WL. Abnormal reproductive development in rats after neonatally administered Antiestrogen (Tamoxifen). Biol Reprod. 1979 Dec 1;21(5):1087–90PubMedGoogle Scholar
  311. 311.
    Iguchi T, Hirokawa M, Takasugi N. Occurence of genital tract abnormalities and bladder hernia in female mice exposed neonatally to tamoxifen. Toxicology. 1986; 42(1):1–11PubMedGoogle Scholar
  312. 312.
    Tucker M, Adam H, Patterson J. Tamoxifen. In: Laurence DR, McLean AEM, Wetherall M, editors. Safety testing of new drugs laboratory predictions and clinical performance. Academic, London; 1984. p. 125–61 [chapter 6]Google Scholar
  313. 313.
    Barthelmes L, Gateley CA. Tamoxifen and pregnancy. Breast. 2004;13(6):446–51PubMedGoogle Scholar
  314. 314.
    Andreadis C, Charalampidou M, Diamantopoulos N, Chouchos N, Mouratidou D. Combined chemotherapy and radiotherapy during conception and first two trimesters of gestation in a woman with metastatic breast cancer. Gynecol Oncol. 2004 Oct;95(1):252–5PubMedGoogle Scholar
  315. 315.
    Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy-case report and literature review. Gynecol Oncol. 2001 Mar; 80(3):405–8PubMedGoogle Scholar
  316. 316.
    Cullins SL, Pridjian G, Sutherland CM. Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation. JAMA. 1994 June 22–29;271(24): 1905–6PubMedGoogle Scholar
  317. 317.
    Tewari K, Bonebrake RG, Asrat T, Shanberg AM. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet. 1997 Jul 19;350(9072):183PubMedGoogle Scholar
  318. 318.
    Goldhirsch A, Gelber RD. Life with consequences of breast cancer: pregnancy during and after endocrine therapies. Breast. 2004;13(6):443–5PubMedGoogle Scholar
  319. 319.
    Delozier T, Switsers O, Genot JY, Ollivier JM, Hery M, Namer M, et al Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial). Ann Oncol. 2000 May 1;11(5):515–9PubMedGoogle Scholar
  320. 320.
    Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG. 2004 Sep;111(9):940–3PubMedGoogle Scholar
  321. 321.
    Cowchock S. Prevention of fetal death in the antiphospholipid antibody syndrome. Lupus. 1996 Oct;5(5):467–72PubMedGoogle Scholar
  322. 322.
    Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999 Sep 17;86(3):242–4PubMedGoogle Scholar
  323. 323.
    Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000 Dec;62(6):385–92PubMedGoogle Scholar
  324. 324.
    Bilgin K, Yaramis A, Haspolat K, Tas MA, Gunbey S, Derman O. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics. 2001 Jan;107(1):36–41PubMedGoogle Scholar
  325. 325.
    Schibler KR, Osborne KA, Leung LY, Le TV, Baker SI, Thompson DD. A randomized, placebo-controlled trial of granulocyte colony-stimulating factor administration to newborn infants with neutropenia and clinical signs of early-onset sepsis. Pediatrics. 1998 Jul;102(1 Pt 1):6–13PubMedGoogle Scholar
  326. 326.
    Sangalli MR, Peek M, McDonald A. Prophylactic granulocyte colony-stimulating factor treatment for acquired chronic severe neutropenia in pregnancy. Aust NZ J Obstet Gynaecol. 2001 Nov;41(4):470–1Google Scholar
  327. 327.
    Ghosh A, Ayers KJ. Darbepoetin alfa for treatment of anaemia in a case of chronic renal failure during pregnancy-case report. Clin Exp Obstet Gynecol. 2007;34(3):193–4PubMedGoogle Scholar
  328. 328.
    Byrne J, Rasmussen SA, Steinhorn SC, Connelly RR, Myers MH, Lynch CF, et al Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet. 1998 Jan;62(1):45–52PubMedGoogle Scholar
  329. 329.
    Dodds L, Marrett LD, Tomkins DJ, Green B, Sherman G. Case-control study of congenital anomalies in children of cancer patients. BMJ (Clinical Research ed.) 1993 July 17;307(6897):164–8Google Scholar
  330. 330.
    Edgar AB, Wallace WHB. Pregnancy in women who had cancer in childhood. Eur J Cancer. 2007;43(13):1890–4PubMedGoogle Scholar
  331. 331.
    Li FP, Fine W, Jaffe N, Holmes GE, Holmes FF. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst. 1979 May;62(5):1193–7PubMedGoogle Scholar
  332. 332.
    Mulvihill JJ, Myers MH, Connelly RR, Byrne J, Austin DF, Bragg K, et al Cancer in offspring of long-term survivors of childhood and adolescent cancer. Lancet. 1987 Oct 10;2(8563):813–7PubMedGoogle Scholar
  333. 333.
    Winther JF, Boice JD Jr, Mulvihill JJ, Stovall M, Frederiksen K, Tawn EJ, et al Chromosomal abnormalities among offspring of childhood-cancer survivors in Denmark: a population-based study. Am J Hum Genet. 2004;74(6):1282–5PubMedGoogle Scholar
  334. 334.
    Hensley ML, Reichman BS. Fertility and pregnancy after adjuvant chemotherapy for breast cancer. Crit Rev Oncol Hematol. 1998;28(2):121–8PubMedGoogle Scholar
  335. 335.
    Calhoun K, Hansen N. The effect of pregnancy on survival in women with a history of breast cancer. Breast Dis. 2005;23:81–6PubMedGoogle Scholar
  336. 336.
    Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: “healthy mother effect”. Am J Obst Gynecol. 1994 Mar;170(3): 818–23Google Scholar
  337. 337.
    Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment? Lancet. 1997 Aug 2;350(9074): 319–22PubMedGoogle Scholar
  338. 338.
    Harvey JC, Rosen PP, Ashikari R, Robbins GF, Kinne DW. The effect of pregnancy on the prognosis of carcinoma of the breast following radical mastectomy. Surg Gynecol Obstet. 1981 Nov;153(5):723–5PubMedGoogle Scholar
  339. 339.
    Clark RM, Chua T. Breast cancer and pregnancy: the ultimate challenge. Clin Oncol (Royal College of Radiologists (Great Britain)). 1989 Sept;1(1):11–8Google Scholar
  340. 340.
    Mueller BA, Simon MS, Deapen D, Kamineni A, Malone KE, Daling JR. Childbearing and survival after breast carcinoma in young women. Cancer. 2003 Sep 15;98(6):1131–40PubMedGoogle Scholar
  341. 341.
    Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. Teratology. 1994 Feb;49(2):79–81PubMedGoogle Scholar
  342. 342.
    Wobbes T. Effect of a breast-saving procedure on lactation. The European journal of surgery = Acta Chirurgica. 1996 May;162(5):419–20PubMedGoogle Scholar
  343. 343.
    Findlay PA, Gorrell CR, d’ Angelo T, Glatstein E. Lactation after breast radiation. Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):511–2PubMedGoogle Scholar
  344. 344.
    Hassey KM. Pregnancy and parenthood after treatment for breast cancer. Oncol Nurs Forum. 1988 Juyl–Aug;15(4): 439–44PubMedGoogle Scholar
  345. 345.
    Higgins S, Haffty BG. Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer. 1994 Apr 15;73(8):2175–80PubMedGoogle Scholar
  346. 346.
    Zimpelmann A, Kaufmann M. Breastfeeding nursing after breast surgery. Zentralbl Gynakol. 2002 Nov;124(11):525–8PubMedGoogle Scholar
  347. 347.
    Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst. 1994;16:191–7Google Scholar
  348. 348.
    Northouse LL. Breast cancer in younger women: effects on interpersonal and family relations. J Natl Cancer Inst. 1994;16):183–90Google Scholar
  349. 349.
    Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, et al Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer. Psycho-Oncol. 2007;16(10):895–903Google Scholar
  350. 350.
    Oddens BJ, den Tonkelaar I, Nieuwenhuyse H. Psychosocial experiences in women facing fertility problems — a comparative survey. Hum Reprod (Oxford, England). 1999 Jan; 14(1):255–61Google Scholar
  351. 351.
    The Ethics Committee of the American Society for Reproductive Medicine Fertility preservation and reproduction in cancer patients. Fertil Steril. 2005;83(6):1622–8Google Scholar
  352. 352.
    Dow KH. Having children after breast cancer. Cancer Pract. 1994 Nov–Dec; 2(6):407–13PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.IBCSG Coordinating Center and InselspitalBerneSwitzerland
  2. 2.International Breast Cancer Study GroupBernSwitzerland

Personalised recommendations